In human clinical studies, low dose of IL-2 (LDIL-2) has been used in small cohorts of patients with systemic lupus erythematosus (SLE), chronic graft versus host disease (GVHD), Type 1 diabetes (T1D), and Hepatitis C virus (HCV) related vasculitis. This evidence concerns the gene IL2 and systemic lupus erythematosus.